Show simple item record

AuthorRadwan, Esam M.
AuthorAbdullah, Rasedee
AuthorAl-Qubaisi, Mothanna Sadiq
AuthorEl Zowalaty, Mohamed E.
AuthorNaadja , Seif-Eddine
AuthorAlitheen, Noorjahan B.
AuthorOmar, AbdulRahman
Available date2021-09-01T10:04:05Z
Publication Date2016
Publication NameMolecular Medicine Reports
ResourceScopus
URIhttp://dx.doi.org/10.3892/mmr.2016.4989
URIhttp://hdl.handle.net/10576/22530
AbstractPatients with cancer often exhibit signs of anemia as the result of the disease. Thus, cancer chemotherapies often include erythropoietin (EPO) in the regime to improve the survival rate of these patients. The aim of the present study was to determine the effect of EPO on doxorubicin-treated breast cancer cells. The cytotoxicity of doxorubicin alone or in combination with EPO against the MCF-7 and MDA-MB‑231 human breast cancer cells were determined using an MTT cell viability assay, neutral red (NR) uptake assay and lactate dehydrogenase (LDH) assay. The estimated half maximal inhibitory concentration values for doxorubicin and the combination of doxorubicin with EPO were between 0.140 and 0.260 µg/ml for all cells treated for 72 h. Treatment with doxorubicin in combination with EPO led to no notable difference in cytotoxicity, compared with treatment with doxorubicin alone. The antiproliferative effect of doxorubicin at a concentration of 1 µg/ml on the MDA‑MB‑231 cells was demonstrated by the decrease in viable cells from 3.6x105 at 24 h to 2.1x105 at 72 h of treatment. In order to confirm apoptosis in the doxorubicin-treated cells, the activities of caspases-3/7 and ‑9 were determined using a TBE assay. The results indicated that the activities of caspases-3/7 and ‑9 were significantly elevated in the doxorubicin-treated MDA-MB-231 cells by 571 and 645%, respectively, and in the MCF 7 cells by 471 and 345%, respectively, compared with the control cells. EPO did not modify the effect of doxorubicin on these cell lines. The results of the present study suggested that EPO was safe for use in combination with doxorubicin in the treatment of patients with breast cancer and concurrent anemia
Languageen
PublisherSpandidos Publications
Subjectcaspase 3
caspase 7
caspase 9
DNA
doxorubicin
lactate dehydrogenase
neutral red
recombinant erythropoietin
antineoplastic agent
doxorubicin
EPO protein, human
erythropoietin
recombinant protein
antiproliferative activity
apoptosis
Article
breast cancer
breast cancer cell line
cancer combination chemotherapy
cell proliferation
cell viability
concentration response
controlled study
DNA fragmentation
drug cytotoxicity
drug efficacy
drug mechanism
enzyme activity
human
human cell
IC50
MCF 7 cell line
mda mb 231 cell line
monotherapy
MTT assay
uptake assay
Breast Neoplasms
cell survival
drug effects
female
MCF-7 cell line
metabolism
pathology
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Cell Proliferation
Cell Survival
Doxorubicin
Erythropoietin
Female
Humans
MCF-7 Cells
Recombinant Proteins
TitleEffect of recombinant human erythropoietin and doxorubicin in combination on the proliferation of MCF-7 and MDA-MB231 breast cancer cells
TypeArticle
Pagination3945-3952
Issue Number5
Volume Number13
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record